Volume 3.16 | May 1

Pulmonary Cell News 3.16 May 1, 2014
Pulmonary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pulmonary Cell News on Twitter
Differentiation of Mouse Induced Pluripotent Stem Cells into Alveolar Epithelial Cells In Vitro for Use In Vivo
Scientists modified a two-step protocol for embryonic stem cells that resulted in a yield of ~9% surfactant protein C+ alveolar epithelial type II (AEC II) cells from mouse induced pluripotent stem cells (iPSCs) in a 12-day period. The differentiated iPSCs showed morphological characteristics similar to those of AEC II cells. [Stem Cells Transl Med] Abstract
[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
PUBLICATIONS (Ranked by impact factor of the journal)
Efficient Bioactive Delivery of Aerosolized Drugs to Human Pulmonary Epithelial Cells Cultured at Air-Liquid Interface Conditions
The authors introduce the ALICE-CLOUD technology, which utilizes principles of cloud motion for fast and quantitative delivery of aerosolized liquid drugs to pulmonary cells cultured under realistic air-liquid interface conditions. [Am J Respir Cell Mol Biol] Abstract

Lymphocyte-Derived Microparticles Induce Apoptosis of Airway Epithelial Cells through Activation of p38 MAPK and Production of Arachidonic Acid
Scientists used bronchial and lung tissue cultures to confirm the pro-apoptotic effects of lymphocyte-derived microparticles (LMPs). In cell culture experiments, they found that LMPs induced human airway epithelial cell apoptosis with associated increases in caspase-3 activity. [Apoptosis] Abstract

Brd4 Is Essential for IL-1ß-Induced Inflammation in Human Airway Epithelial Cells
Human primary epithelial cells and BEAS-2B cell lines were stimulated with IL-1ß in the presence or absence of H2O2 and the effect of pre-treatment with bromodomain inhibitors was investigated. [PLoS One] Full Article

Global Gene Expression Profiling of Human Bronchial Epithelial Cells Exposed to Airborne Fine Particulate Matter Collected from Wuhan, China
Scientists aimed to identify genes and pathways that may contribute to particulate matter (PM)2.5-induced lung toxicity in humans through genome-wide approaches. Human bronchial epithelial cells, exposed to various concentrations of PM2.5 collected from Wuhan, China, showed decreased cell viability in a dose-dependent manner. [Toxicol Lett] Abstract

Azithromycin Inhibits Double-Stranded RNA-Induced Thymic Stromal Lymphopoietin Release from Human Airway Epithelial Cells
Investigators explored effects of azithromycin on dsRNA-induced thymic stromal lymphopoietin in normal human bronchial epithelial cells. [Exp Biol Med] Full Article


YB-1 Promotes Transcription of Cyclin D1 in Human Non-Small-Cell Lung Cancers
Scientists showed YB-1 is involved in the transcription of cyclin D1 in human lung cancer. Depletion of endogenous YB-1 by siRNA inhibited progression of G1 phase and down-regulated both the protein and mRNA levels of cyclin D1 in human lung cancer cells. [Genes Cells] Abstract

Antitumor Activity of a Polysaccharide from Longan Seed on Lung Cancer Cell Line A549 In Vitro and In Vivo
Researchers showed that water-soluble longan seed polysaccharide had the ability to cause cell cycle arrest in G1 phase, activation of caspases 3 and 9, and cleavage of poly[ADP (ribose)] polymerase in A549 cells. [Tumor Biol] Abstract

Stat3 Inhibits Beclin 1 Expression through Recruitment of HDAC3 in Nonsmall Cell Lung Cancer Cells
Researchers demonstrated that Beclin 1 is a direct transcriptional target of signal transducer and activator of transcription 3 (Stat3) in lung cancer cells. Interleukin-6 treatment or transfection of a constitutively activated Stat3 in AGS and NCI-H1650 cells inhibited Beclin 1 expression. [Tumor Biol] Abstract

Auricularia polytricha Polysaccharides Induce Cell Cycle Arrest and Apoptosis in Human Lung Cancer A549 Cells
The anticancer activity of Auricularia polytricha polysaccharides towards A549 human lung cancer cells and its underlying mechanisms were investigated. [Int J Biol Macromol] Abstract

Nitric Oxide Mediates Cell Aggregation and Mesenchymal to Epithelial Transition in Anoikis-Resistant Lung Cancer Cells
Cancer cell aggregation has been long known to facilitate metastatic potential of cancer cells. In addition, the presence of nitric oxide in cancer area may have a significant impact on aggregation behavior of the cells. Scientists showed that lung cancer H460 cells possessing high ability of anoikis resistance formed loose aggregates in detached condition. [Mol Cell Biochem] Abstract

View On-Demand Webinar: Optimized Differentiation of Bronchial Epithelial Cells
Emerging Therapeutic Interventions for Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis is a devastating and relentlessly progressive lung disorder. The authors discuss existing therapies and highlight some of the recent, novel therapeutics being explored in the current clinical landscape for the treatment of this chronic, disabling disorder. They also discuss the pathogenic rationale behind current therapies. [Expert Opin Investig Drugs] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Induces Alterations in Gene Expression and Demonstrates Potential Anticancer Activity in Non-Small Cell Lung Cancers, Malignant Pleural Mesothelioma and Melanomas, Cancers that Are Deficient in Key Metabolic Protein
Polaris Group, collaborating with scientists from numerous institutions reported results from preclinical studies which showed that certain non-small cell lung cancers, malignant pleural mesothelioma and melanomas are more likely to respond to treatment with ADI-PEG 20 if they are deficient in the enzyme argininosuccinate synthetase. [Press release from PR Newswire Association LLC discussing research presented at the 2014 Annual American Association for Cancer Research (AACR) Meeting, San Diego] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.
FDA Grants Orphan Drug Designation for Bayer’s Investigational Ciprofloxacin (Dry Powder for Inhalation) for Treatment of Non-Cystic Fibrosis Bronchiectasis
Bayer HealthCare announced that the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development has granted an orphan drug designation for its investigational Ciprofloxacin dry powder for inhalation for the treatment of non-cystic fibrosis bronchiectasis. [PR Newswire Association LLC] Press Release

Anoro™ Ellipta® Now Available in the US for Treatment of COPD
GlaxoSmithKline plc and Theravance, Inc. announced that Anoro™ Ellipta® , the first once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of chronic obstructive pulmonary disease (COPD), is now available to retail pharmacies in the US. [Theravance, Inc.] Press Release

Novartis Gains FDA Approval for Zykadia™, First Therapy for Patients with ALK+ NSCLC Previously Treated with the ALK Inhibitor Crizotinib
Novartis announced that the US Food and Drug Administration (FDA) has approved Zykadia™ for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. [Novartis] Press Release

Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)
Aradigm Corporation announced the dosing of the first patient in the ORBIT-3 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm’s proprietary formulation of inhaled ciprofloxacin for the treatment of non-cystic fibrosis bronchiectasis. [Aradigm Corporation] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW American Association of Cancer Research (AACR) Precision Medicine Series – Drug Sensitivity and Resistance: Improving Cancer Therapy
June 18-21, 2014
Orlando, United States

Visit our events page to see a complete list of events in the pulmonary cell community.
NEW Postdoctoral Researcher – Metabolomics of Pulmonary Medicine (Karolinska Institute)

NEW Molecular Immunologist – COPD (GlaxoSmithKline)

NEW Research Technologist – hPSC (STEMCELL Technologies Inc.)

Postdoctoral Research Associate – Lung Injury and Repair (University of Illinois)

Postdoctoral Scholar – Molecular Mechanisms of Lung Cancer, Lung Regeneration and Lung Development (University of California, San Francisco)

Postdoctoral Research Associate – Extracellular Microenvironment in Cancer (Institute of Translational Medicine, University of Liverpool)

Postdoctoral Opportunity – Mucins, Mucus and Mucociliary Interactions in the Lung (AstraZeneca)

Postdoctoral Positions – Pulmonary and Exercise Immunology (São Paulo Research Foundation)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Pulmonary Cell News: Archives | Events | Contact Us